

Dear colleagues,  
the StKB is pleased to invite you to the

### **3. International StKB Future Workshop Hemo- and Celltherapy Risk Assessment in Platelet Transfusion**

**November 11<sup>th</sup>, 2010; 13 to 17 h**

**New Location: Lecture Hall R, Basement, Building J6  
Hannover medical School (MHH)  
Carl-Neuberg-Street, 30625 Hannover, Germany**

For years, the StKB is intensely engaged in the subject platelet transfusion. The product selection – single donor platelet concentrates (PC) obtained by apheresis versus pooled buffy coat derived PC obtained from 4 to 6 whole blood donations – is one of key issues in this field. The StKB activities to platelet transfusion in 2007 were triggered by the first draft of the German Medical Association “Cross-Sectional Guidelines Hemotherapy” that reduced the product selection to “local availability only”. The StKB responded to this unacceptable proposal by organizing the 1<sup>st</sup> International StKB Future Workshop in Hannover, June 2007 that comprehensively demonstrated the principles of PC supply in Germany and neighbouring countries (e.g. Austria and France) and analyzed the different risk profiles associated with apheresis or pooled PC.

The StKB is now again raising this issue because the debate between advocates of single-donor apheresis PC versus pooled PC is ongoing (Schrezenmeier H, Seifried E et al: Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang 2010). As further aspects around PC production are increasingly gaining importance, highlights of the conference will be:

- The possible impact of pathogen inactivation in the field of platelet transfusion
- The relative safety of pooled whole-blood–derived buffy-coat platelet concentrates
- The British and Swiss strategy on platelet transfusion
- Effects of platelet production require an integral view on the red cell supply
- Legal aspects of disparate risks of platelet products
- Plenum Discussion


The conference will be taped by video recording. The presentation will be in English, conference language is English or German with simultaneous German-English translation. All contributions will be published in a peer reviewed journal.

## General informations and registration:

As the capacity of lecture hall is limited, the organizers of the 3<sup>rd</sup> StKB Future Workshop recommend early registration before September, 1<sup>st</sup>, 2010. Please enrol to the Workshop per email: [hitzler@uni-mainz.de](mailto:hitzler@uni-mainz.de) or by Fax 0049 (0)6131 17473211. The conference will be charged with 20 EURO for StKB members, 50 EURO for non-members, if registered before September 1<sup>st</sup>, 2010; afterwards 40 EURO for StKB members, 100 EURO for non-members. In case of early registration, hotel rooms at a reduced price can be provided.

## !!! New Location:

Lecture Hall R, Basement, Building J6  
Hannover medical School (MHH)  
Carl-Neuberg-Street  
30625 Hannover, Germany



## How to get to the Lecture Hall R, Basement, Building J6:

If you arrive by Taxi, you can stop directly at the entrance of building J6.

If you arrive by tramway (line 4, direction “Roderbruch”), please go to Carl-Neuberg-Street (50 meters), then follow Carl-Neuberg-Street to building J6 (another 100 meters).

## Program

### **3<sup>rd</sup> International StKB Future Workshop Hemo- and Celltherapy**

**Hannover, November 11<sup>th</sup>, 2010; 13 – 17 h**

### **Risk Assessment in Platelet Transfusion**

**Chair: M. Heim, Magdeburg; W. Hitzler, Mainz**

- 13:00-13:05 h Walter Hitzler, Mainz  
Introduction
- 13:05-14:00 h Eleftherios C. Vamvakas, Los Angeles, USA  
The relative safety of pooled whole blood – derived platelet concentrates
- 14:00-14:45 h Stephen Thomas, Brentwood, UK  
The UK strategy for safer platelet transfusion
- 14:45-15:00 h Hans-Gert Heuft, Hannover, Germany  
Donor exposure in platelet transfusion
- 15:00-15:20 h Coffee Break
- 15:20-15:40 h Jean-Louis Kerkhoffs, Amsterdam, NL  
Clinical effectiveness of leucoreduced, pooled PC, stored in plasma or additive solution with and without pathogen reduction
- 15:40-16:00 h Behrouz Mansouri, Bern, Switzerland  
The Swiss strategy on platelet transfusion and implementation of pathogen reduction
- 16:00-16:10 h Robert Zimmermann, Erlangen, Germany  
Effects of platelet production on red cell quality & supply
- 16:10-16:25 h Robert Zimmermann, Erlangen, Germany  
Legal aspects of disparate risks of platelet products
- 16:25-17:00 h Marcell Heim, Magdeburg, Germany  
Plenary Discussion, Farewell

## Speakers:

Priv.-Doz. Dr. med. Behrouz Manosouri-Taleghani, Leitender Arzt, Universitätsklinik für Hämatologie und hämatologisches Zentrallabor, Inselspital/Universitätsspital, CH-3010 Bern. Email: [behrouz.mansouri@insel.ch](mailto:behrouz.mansouri@insel.ch)

Prof. Dr. med. Marcell Heim, Direktor, Institut für Transfusionsmedizin und Immunhämatologie/Blutbank, Universitätsklinikum Otto von Guericke, Leipziger Str. 44, 39120 Magdeburg. Email: [marcell.heim@med.ovgu.de](mailto:marcell.heim@med.ovgu.de)

Dr. med. W. Hitzler, Direktor, Transfusionszentrale, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Hochhaus Augustusplatz, D-55131 Mainz. Email: [hitzler@uni-mainz.de](mailto:hitzler@uni-mainz.de)

Priv.-Doz. Dr. med. Hans-Gert Heuft, Leitender Oberarzt, Institut für Transfusionsmedizin, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, D-30625 Hannover. Email: [heuft.hans-gert@mh-hannover.de](mailto:heuft.hans-gert@mh-hannover.de)

Jean-Louis H. Kerkhoffs, MD, Hematologist, Haga Teaching Hospital, The Hague, Sanquin Southwest Region, Plesmanlaan 1a, 2333 BZ Leiden, The Netherlands. Email: [J.Kerkhoffs@sanquin.nl](mailto:J.Kerkhoffs@sanquin.nl)

Stephen Thomas, PhD, Manager, Component Development Laboratory, NHSBT Brentwood, Crescent Drive, Brentwood, Essex CM15 8DP, UK. Email: [Stephen.Thomas@nhsbt.nhs.uk](mailto:Stephen.Thomas@nhsbt.nhs.uk)

Eleftherios C. Vamvakas, MD, PhD, MPH, Professor and Vice-Chair, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA, USA. Email: [Eleftherios.Vamvakas@cshs.org](mailto:Eleftherios.Vamvakas@cshs.org)

Prof. Dr. med. Robert Zimmermann, Leitender Oberarzt, Abteilung Transfusionsmedizin und Hämostaseologie, Universitätsklinikum Erlangen, Universitätsstr. 12, D-91054 Erlangen. Email: [robert.zimmerman@uk-erlangen.de](mailto:robert.zimmerman@uk-erlangen.de)